PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.

Authors

null

Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy

Ugo De Giorgi , Maha H. A. Hussain , Neal D. Shore , Karim Fizazi , Bertrand Tombal , David F. Penson , Fred Saad , Eleni Efstathiou , Katarzyna Madziarska , Joyce Leta Steinberg , Jennifer Sugg , Xun Lin , Qi Shen , Cora N. Sternberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02003924

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 84)

DOI

10.1200/JCO.2021.39.6_suppl.84

Abstract #

84

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters